Teva Pharmaceutical Industries to donate over $7M in medicine to benefit earthquake victims in Haiti

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it will be donating over $7 million in medicine to benefit earthquake victims in Haiti. Teva is working with several of its Non-Governmental Organization (NGO) partners to ensure these drugs are delivered to Haiti without delay.

“As a company, Teva was devastated to hear about the earthquake and our hearts and thoughts go out to the country of Haiti”

“As a company, Teva was devastated to hear about the earthquake and our hearts and thoughts go out to the country of Haiti,” said Shlomo Yanai, Teva’s President and Chief Executive Officer. “Working with our partners, we are providing essential medical products to assist in the relief efforts.”

Teva, the largest generic pharmaceutical company in the world is proud to fulfill one of its leading values – making quality medicine accessible around the world – especially where and when it is needed most.

Teva will also match contributions made by its employees to designated charities around the world.

Source:

Teva Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)